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Abstract 
Comparative clinical studies of children and adults with immune thrombocytopenia (ITP) are poorly 
covered in the literature. However, the accepted classification of ITP —childhood ITP and adult ITP—
results in considerable differences in treatment protocols and practice guidelines. The analysis of the 
Pediatric and Adult Registry on Chronic ITP (PARC-ITP) of patients at first presentation 
demonstrated fewer differences in clinical and laboratory findings at initial diagnosis between children 
and adults than expected. The present report of 2-year follow-up data supports the hypothesis that 
there are common aspects of childhood and adult ITP. Data of 3360 children and 420 adults were 
collected during the time of 2004 until 2015 at initial diagnosis. Follow-up information was available 
for 51% and 33% of children and 66% and 49% of adults at 12- and 24-months, respectively. 
Similarities were found in unexpected areas of ITP, such as the rate of late remission at 12 and 24 
months, reported bleeding sites, platelet count in bleeders, and the frequency of treated patients with 
persistent or chronic ITP. Differences were confirmed for the overall rate of remission and treatment 
modalities. Unexpected differences were found in the percentage of non-bleeders, with more adults in 
the non-bleeder group. More studies are needed to investigate different age groups with the aim to 
optimize their management. 
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Introduction 
 
Immune thrombocytopenia (ITP) is a diagnosis of exclusion and can be caused by multiple disease 
mechanisms including a variety of antiplatelet autoantibodies, cytotoxic T lymphocyte-mediated 
platelet destruction, T- and B-cell abnormalities with disturbed cytokine profiles, and impaired 
megakaryopoiesis.1-5 Clinically, ITP of children differs from that of adults in spontaneous remission 
rate, bleeding pattern, and treatment need.
6-10
 While approximately 80% of children are disease-free 
within 1 year, most adults (70%–80%) show a chronic course.11 Adults have a higher bleeding risk; 
thus, pharmacological treatment and splenectomy are more often required in adults than in children,
9,10
 
whereas a watch and wait strategy is a standard approach for children with no or mild bleeding.9,10 
However, some of these clinical presumptions are limited by inconsistent study designs, study 
populations, collected information (e.g., bleeding assessment tools), definitions, study objectives, and 
end-points. Initial data of the Pediatric and Adult Registry on Chronic ITP (PARC-ITP) were 
previously published and demonstrated considerably smaller differences in clinical and laboratory 
findings at disease onset between children and adults than expected.
12 
Moreover, recent studies showed 
that the severity of thrombocytopenia at diagnosis was a predictor of recovery from ITP in both 
children and adults.
13,14 
The classification of pediatric and adult ITP may not adequately reflect clinical 
requirements. Sub-classifying patients based on phenotypic characteristics, including insidious or 
abrupt onset and grade of bleeding, describe ITP more accurately and consequently affect management 
decisions and probably better predict persistent or chronic ITP. 
Understanding differences and similarities between children and adults with ITP will improve 
individual diagnosis and management. We aimed to assess and interpret comparative follow-up (FU) 
PARC-ITP Registry data in children and adults with ITP. 
 
Methods 
 
The PARC-ITP is an international multi-center registry designed to collect data prospectively in 
children and adults with newly diagnosed ITP. The registry is a project of the Intercontinental 
Cooperative Immune Thrombocytopenia Study Group (ICIS, www.itpbasel.ch) and is based on 
voluntary participation of pediatricians and adult hematologists worldwide. ICIS was founded in 1997 
by pediatric hematologists to analyze multiple diagnostic and therapeutic aspects of ITP. Over the 
years, it was realized that a joint database for children and adults may facilitate better understanding of 
ITP. In May 2004, PARC-ITP was initiated to study the natural history of ITP in all age groups and 
develop and coordinate new hypotheses and projects. 
ICIS is meanwhile well-established and active at various scientific congresses, and holds expert 
meetings every 3 years.
15-19
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The protocol, registration of data, and all registry documents are available via secure internet access 
(www.parc-itp.net). Data acquisition by investigators was performed by direct internet access into a 
database that is administered in the ICIS office in Basel, Switzerland (www.itpbasel.ch). Data are 
continuously registered at the time of diagnosis, at 6 and 12 months, and then yearly and include 
demographics, diagnostics, clinical data, and safety data of treatments. The questionnaires’ structure is 
limited by a certain number of questions to maintain feasibility data transfer and collaboration of 
investigators. Data quality controlling and cleaning is performed at the office in Basel. ITP was 
defined according to the International Working Group (IWG) definitions.20 Patients with missing FU 
data at certain time points (6, 12, and 24 months) were included in the analysis (Supporting 
Information Figure S1A). Secondary ITP was excluded from registration; patients in whom the 
diagnosis was revised from primary to secondary ITP or thrombocytopenia of other cause during FU 
were prospectively identified, and not excluded from the analysis. Ethical committee approval and 
informed consent were received from all patients.
12,21
 
Data are reported using descriptive statistics. Frequencies and percentages are reported for counts and 
categorical variables. Continuous variables are reported as mean ± standard deviation (SD). Median 
and interquartile range (IQR) are reported for age and platelet count in Table 1.  
Categorical variables were analyzed using Chi-square tests. Continuous variables between groups 
were compared using the non-parametric Wilcoxon’s test. Cumulative incidences between groups 
were compared using the non-parametric log-rank test. A p-value of <0.05 was considered statistically 
significant. Analyses were performed using R Development Core Team, version 3.4.0. 22 
 
Definitions 
If not mentioned otherwise, the definitions of the IWG were used.
20
 
Patients were divided into two groups according to age at initial diagnosis. Children were defined as 3 
months to 16 years of age, and adults as >16 years. For certain analyses, the adult group was divided 
into three subgroups including young adults (16–40 years), midlife adults (40–60 years), and seniors 
(> 60 years). Age refers to the age at first presentation of ITP, equating to the initial visit. 
FU data at 6 months summarize the clinical course (e.g., bleeding and management) of the disease in 
the first 6 months (excluding information at initial diagnosis); FU data at 12 months summarize the 
clinical course during >6–12 months, and FU data at 24 months include the time during >12–24 
months. Platelet counts were registered as a single value (mean ± SD) at approximately 6 (175 ± 47 
days), 12 (365 ± 66 days), and 24 months (722 ± 59 days). 
Remission of ITP: “Remission” in an autoimmune disease refers to the reoccurrence of tolerance and is 
difficult or even impossible to measure. We used the term “remission” to define ITP activity as 
assessed by the platelet count irrespective of prior or ongoing therapy. According to our definition, a 
platelet count of >100 × 109/L at 6, 12, and 24 months of follow-up visits is considered a “remission.” 
Persistent ITP was defined as a platelet count <100 × 109/L at 6 months, and chronic disease as a 
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platelet count <100 × 109/L at 12 and/or 24 months. According to the IWG, the definition of persistent 
ITP covers the period between 3 and 12 months. The registry only records data at 6 months. Ongoing 
ITP was defined as patients with persistent or chronic ITP. Late remission at 12 months characterized 
patients with ongoing disease at 6 months but who were in remission at 12 months. Late remission at 
24 months characterized patients with ongoing disease at 6 and/or 12 months but who were in 
remission at 24 months.  
Bleeding was defined as any bleeding event in the last recorded time period, independently of intensity 
or frequency. Location of bleeding was recorded for all bleeding events in the last time period and not 
per event.  
Corticosteroid therapy was defined as any form of corticosteroids irrespective of dosage or 
administration route. Hence, high-dose and pulsed therapies were included in this definition. Seconda 
and third-line treatment was defined as drugs other than corticosteroids, IVIG and Anti-D. Relevant 
co-medication was defined as drugs with known effects on hemostasis [anti-inflammatory drugs 
(NSAID), anticoagulants, and platelet antagonists].  
Co-morbid conditions were defined as one or more of the following conditions at initial registration: 
arterial hypertension, diabetes mellitus, gastrointestinal disease, thyroid disease, cancer, alcohol abuse, 
cardiovascular disease, rheumatoid arthritis (RA), psoriasis, systemic lupus erythematosus, recent 
major general surgery, acute respiratory failure, chronic obstructive pulmonary disease, infectious 
disease, obesity, recent knee or hip replacement surgery (<1 year), and splenomegaly. 
Patients lost to FU at a specific visit were defined as patients who missed the relevant visit and all 
following visits, including those who have been discharged because of improvement of 
thrombocytopenia. 
 
Results 
In total, 3780 evaluable patients with primary ITP were included between May 2004 and November 
2015 (Supporting Information Figure S1A). Data were provided by 84 investigators of 74 participating 
sites in 31 countries. The 10 most active centers are listed according to total patient number: China, 
Argentina, United Kingdom, Egypt, Israel, Italy, and Germany and together registered 2101 patients 
(56%). Number of countries, institutions, and patients registered in the PARC-Registry are 
demonstrated in Table S1 (Supporting Information).  FU information was available for the 6-, 12-, and 
24-month evaluations in 68%, 51%, and 33% of children and 79%, 66%, and 49% of adults, 
respectively (Supporting Information Figure S1B). 
 
Initial patient characteristics 
Data at the time of first presentation included 3360 children (89%) and 420 adults (11%). The adult 
subgroups consist of 250 young adults, mean age 24.2 years (SD 7.3) , 101 midlife adults, mean age 
50.2 years (SD 5.4), and 69 seniors, mean age 60.8 (SD 7.2). The age distribution of young adults, 
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midlife adults, and seniors at the 12-month visit was similar to that at baseline. The male:female ratio 
was in favor of male patients in children (1.09:1) and female patients in adults (0.54:1). Mean age of 
all children was 5.2 ± 4.1 years and that of adults was 38 ± 19 years. 
“Relevant co-medication” was reported in 10.7% (45) of adults and in 2% (68) of children. However, 
young adults showed a low relevant co-medication rate (3.6%) similar to that of children compared 
with midlife adults (10.9%) and seniors (36.2%). Anti-inflammatory drug use only (e.g., NSAIDs) was 
reported in 60% of adults and 97% of children in whom relevant co-medication was reported. 
Co-morbidities were reported in 360 children, 32 young adults, 42 midlife adults, and 55 seniors 
(10.7%, 12.8%, 41.6%, and 79.7%, respectively).  
 
Lost to FU 
Lost to FU was significantly higher in patients achieving remission of ITP. At 6 and 12 months, 
remission rates in children subsequently lost to FU were 87% and 82%, respectively (chi-square test 
comparing remission state of patients with and without FU, p < 0.001 at both time points). In adults, 
remission rates were 64% (p = 0.008) and 56% (p = 0.15), respectively. Among all patients with 
persistent ITP at 6 months, FU information at 12 and/or 24 months was provided for 90% of children 
and adults. Comparison of the initial characteristics between patients with FU data and patients lost to 
FU at 6 months found that children lost to FU had a lower age, higher initial mean platelet count, 
lesser initial bleeding, and lesser initial drug treatment (Table 1). 
 
Natural history: remission and ongoing disease 
The characteristics of patients in remission and with ongoing disease at 12 months are shown in Table 
2 and mean platelet counts at all FU are depicted in Figure 1A. Patients in remission at 6, 12, and 24 
months consisted of 70%, 71%, and 71% of children and 45%, 49%, and 56% of adults, respectively. 
Among the patients with persistent ITP, 212/592 (36%) children and 42/155 (27%) adults achieved 
remission at 12 months. Late remission at 24 months was reported in 83/298 (28%) and 26/87 (30%) 
adults. The cumulative incidence of remission was significantly different between children and adults 
(p < 0.001) and is demonstrated in Figure 2. For this analysis, patients achieving remission at 6 and/or 
12 months and consequently lost to FU were presumed to be still in remission at the 24-month FU. 
In children, mean age of patients with late remission at 12 and 24 months was higher (6.9 ± 4.7 years) 
than that of children with reported early remission at 6 months (4.8 ± 4 years) (p < 0.001). Children 
with persistent ITP had a mean age of 7.2 ± 4.6 years. Adults with early remission at the 6-month FU 
had a mean age of 37.9 ±18.5 years and those with a late remission at 12 and 24 months had a mean 
age of 40.4 ± 20.4 years, which was not significant (p = 0.45). 
Mean platelet count in patients with ongoing ITP was very similar in children and adults at the 12-
month FU: 46 ± 29 × 109/L and 51 ± 26 × 109/L, respectively. Children in remission showed a higher 
platelet count at all FU examinations compared with adults (Figure 1A). 
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Bleeding manifestations 
Approximately 37% and 36% of children diagnosed with chronic ITP reported no bleeding at 12 and 
24 months, respectively. A higher percent of adults with chronic ITP had no bleeding manifestations 
(69% and 64% at 12 and 24 months, respectively) (p < 0.001 at both time points). Children and adults 
achieving remission showed very similar percentages of non-bleeders at all reported FU examinations 
(e.g. Table 2). 
The bleeding sites showed similarities in children and adults at all FU examinations (Supporting 
Information Table S2). Cutaneous bleeding, oral cavity bleeding, and epistaxis were the main bleeding 
sites. No major difference in bleeding sites was found between patients achieving remission and 
patients with chronic ITP. Occurrence of menorrhagia was similar in adults (16–50 years) and 
adolescents (13–16 years) in patients with ongoing ITP at 6 months (12.2% and 13.8%, respectively) 
and 12 months (7.8% and 4.9%, respectively). Information about actual numbers of bleeding events 
and their severity was not recorded. Mean platelet count in bleeders with chronic ITP (at the12-month 
FU) was 36 ± 26 × 10
9
/L in children and 40 ± 25 × 10
9
/L in adults and in non-bleeders, 63 ± 25 × 10
9
/L 
and 56 ± 25 × 10
9
/L, respectively. 
During the overall study period, intracranial hemorrhage (ICH) was reported in 20 children (0.6%) and 
seven adults (1.7%). Characteristics of patients with ICH are shown in Table S3 (Supporting 
Information).  
Co-morbidities did not appear to affect bleeding in children or adults; approximately 69% and 66% of 
children and 44% and 43% of adults with and without co-morbidities with persistent ITP at 6 months 
reported bleeding, respectively. This was also observed in adults on relevant co-medication; only 22% 
of adults diagnosed with chronic ITP and taking relevant co-medication reported a bleeding event 
compared with 32% of those without co-medication. The group of children on relevant co-medication 
was too small for a detailed analysis. 
 
Management 
Platelet-enhancing drug treatment was reported at the 6-month FU (initial treatment not included), 12- 
and 24-month FU  in 30%, 19% and 19% of children and in 59%, 40% and 33% of adults, 
respectively. However, for patients with ongoing ITP, treatment did not differ between children and 
adults (58%, 46%, and 47%; and 58%, 52%, and 40% at the three FU examinations, respectively). 
Women with ongoing disease were more often treated than men (Table 2). The platelet counts of 
treated and untreated patients with chronic ITP are shown in Figure 1B. 
 
First-line treatment (corticosteroids andIVIG) 
Corticosteroids were prescribed in 19% of children and 49% of adults during the first 6 months of the 
disease (initial treatment excluded). Corticosteroid use decreased in both children and adults over time, 
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with 12% and 11% of children and 33% and 21% of adults receiving corticosteroids at 12 and 24 
months, respectively. However, the proportion of patients receiving corticosteroids in the group of 
patients requiring treatment remained high at all three FU examinations (adults, 83%, 81%, and 65%; 
and children, 65%, 63%, and 56%, respectively). Immunoglobulin (IVIG and anti-D) use was higher 
in children than in adults at all three FU examinations (e.g. Table 2). 
 
Second (third)-line treatment 
Second (third)-line drug treatment was reported in 38%, 47%, and 44% of treated children and 67%, 
74%, and 72% of adults at 6-, 12-, and 24-month FU, respectively. The modality of treatment was not 
analyzed for this report. Splenectomy was performed in 4 children and 23 adults within the first 6 
months (0.2% and 7.1% of children and adults). In 2/4 children, the reason for performing 
splenectomy was not obvious in the questionnaire. Splenectomy was performed in 13 (0.8%) and 13 
(1.2%) children and in 14 (5.2%) and 8 (4.1%) adults during 6–12 months and 12–24 months, 
respectively. The female:male ratio of splenectomized patients was in favor of females in adults (67%) 
and also in children to a lesser extent (57%). Between May 2004 and January 2008, 35 splenectomies 
(0.8 total cases/month; adults, 0.5/month; children, 0.3/month) were performed; between 2008 and 
November 2015 39 splenectomies were performed (0.4 total cases/month; adults, 0.2/month; children, 
0.2/month). Remission rate after splenectomy (at 6 or 12 months) was 54% in children and 70% in 
adults at the next FU, with no difference between the two FU times. In 4 children (13%) and 6 adults 
(14%), the remission state was unknown. 
 
Discussion 
Comparative clinical studies of pediatric and adult ITP are rare and based on retrospective data.
23,24
 
PARC-ITP represents the first prospective observational cohort of children and adults with ITP and 
allows direct comparison of children and adults. 
Differences between pediatric and adult ITP have been traditionally emphasized6 and appear to be 
opinion-based rather than evidence-based.7-10 Incongruity of definitions and lack of comparative data 
might have further contributed to the separation of childhood and adulthood ITP.
25 
In most 
textbooks,
26,27 
pediatric ITP is described as an acute and profound but self-limiting thrombocytopenia 
following a viral infection, with a low life-threatening bleeding risk. In contrast, adult ITP is described 
as a chronic disease with an insidious onset and a moderate thrombocytopenia, sometimes detected as 
an incidental thrombocytopenia, a high bleeding risk for patients with a platelet count <30 × 109/L 
(40), and increased morbidity and mortality, particularly in patients aged >60 years.11,25,28,29 Current 
concepts of pediatric and adult ITP resulted in treatment protocols and practice guidelines with 
clinically relevant differences between these groups.7-10 
PARC-ITP first data analysis of children and adults with newly diagnosed ITP revealed surprising 
similarities in presenting platelet count, likelihood of overall bleeding when platelets were <20 × 
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10
9
/L, and percentage of patients who remained untreated in both populations.
12 
Patients differed with 
regard to co-morbidities and initial treatment modality. Pediatric and adult ITP seem to share more 
common clinical and laboratory aspects than previously presumed. This report is an analysis of FU 
data and supports the hypothesis of common aspects among children and adults. Similarities were 
found in many unexpected areas of ITP regarding natural history, including late remission rate at 12 
and 24 months, reported bleeding sites, platelet count in bleeders, and need to treat patients with 
persistent or chronic ITP. Differences were confirmed for the overall remission rate and treatment 
modalities. Unexpected differences were found regarding the percentage of non-bleeders.Age group 
were arbitrary chosen. The age of thepediatric cohort corresponds to data previously reported in the 
literature,30 the adult cohort  was slightly younger than that reported e.g. by Abrahamson and 
coworkers
31 32
, the difference here could be explained based on our definition of adults aged >16 years. 
 
Remission 
Remission rate in adults (45% at 6-month FU) was higher than expected6,7 .In adults, we could not 
differentiate patients in remission still receiving ITP treatment from those with sustained remission 
after discontinuing treatment. In children, remission rate was comparable to earlier reports33, so as 
differences in age between patients with early remission (until 6 months) and those with persistent or 
chronic disease (4.9 ± 4 years, 7.2 ± 4.6 years, and 7.4 + 4.5 years, respectively).33 Children with late 
remission (at 12 or 24 months) were older (6.9 ± 4.7 years) than patients with early remission in our 
cohort. 
Late remission at 12- and 24-month FU examinations was very similar in children (36% and 28% of 
patients with ongoing ITP at the previous FU) and adults (28% and 30%). Late remission data in 
adults are scarce,
34 
and this is neglected in some publications involving therapeutic recommendations, 
particularly the time point of splenectomy.8,10 Sailer et al34 showed that between 6 months and 3 years 
after diagnosis, adults with severe ITP (<20 × 10
9
/L platelets) had a 0.5% chance per month of 
obtaining complete remission during treatment with or without low-dose steroids and reported a 61% 
cumulative probability of complete remission in not splenectomized patients. In children, ICIS 
reported a late remission rate of 16%–25% between 6 and 12 months
33,35
 and 24% between 12 and 24 
months;24 however, the definition of remission was a platelet count >150 × 109/L, which may explain 
the small difference with our study. 
 
Bleeding 
Definition, assessment, and grading of bleeding in patients with ITP has been developed with 
consensus conferences20 and use of bleeding scores.36,37 Unfortunately, there is no consensus on which 
bleeding assessment tool should be used in a routine clinical setting and at which time point or in 
which clinical situation bleeding should be assessed. Bleeding assessment is further hindered by the 
lack of clear inclusion criteria of study populations.
28,38-41
 We focused on the analysis of non-bleeders 
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because the definition is clearer. However, diagnosing a “non-bleeder” requires a complete clinical 
assessment. More adults with persistent or chronic ITP exhibited a non-bleeding phenotype (e.g., 69% 
at the 12-month FU) than children (37%), despite similar platelet counts in both. However, bleeding 
sites were similar among them, particularly at 24 months of FU, with the same proportions of 
mucocutaneous bleeding and hematuria in the two age groups. In a systematic review of the literature, 
Neunert et al. revealed more severe bleeding events in children than in adults, excluding ICH.41 This 
information together with our data contradicts the widely accepted paradigm that adults have a higher 
bleeding complication risk. Nevertheless, according to literature, elderly patients (>60 years) still have 
an increased bleeding risk.
11,28,29,42 
The number of elderly patients in PARC-ITP (69) was too small to 
be analyzed separately. Overall ICH incidence in our cohort was 0.6% in children and 1.7% in adults, 
which is similar to the findings of a recent systematic review of severe bleeding of 0.4% and 1.4%, 
respectively, as well as the results of other reports.25,41,43,44 ICH was reported during initial diagnosis of 
ITP in 14/20 (70%) of children and 7/7 (100%) of adults, corresponding to the results of a study of 40 
children revealing that ICH occurred in 18 (45%) patients within the first 7 days.43 
 
Treatment 
Drug treatment in children and adults with ongoing ITP was similar in both age groups. Indeed, 58% 
of patients with persistent ITP (at 6 months) received platelet-enhancing treatment independently of 
age group, with a small decrease over time in both groups. Therefore, children with ongoing disease 
are not treated less frequently than adults with platelet-enhancing drugs, despite the recommendation 
of a watch and wait strategy in pediatric patients with no or mild bleeding.
9,10
 A possible bias could 
have been that children with active ITP were treated because of bleeding (“on-demand therapy”) 
compared with a certain percentage of adults who probably received platelet-enhancing drugs as 
prophylaxis. However, the treatment rationale was not registered. Differences were seen in the choice 
of treatment modality. In adults, steroids were the preferred therapy at 6- and 12-month FU (84% and 
81% of patients under treatment, respectively) and second (third)-line drugs at 24-month FU (72%). In 
children, steroids (65%, 63%, and 56%) and immunoglobulins (67%, 55%, and 55%) were similarly 
represented at all FU examinations. A decline of steroid use was seen at FU for all patients probably 
because of cumulative toxicity and poor drug acceptance. The percentage of children and adults using 
second (third)-line therapy was relatively stable over time. 
The splenectomy rate was relatively low with a cumulative splenectomy rate until the 24-month FU of 
30/3360 (0.9%) children and 44/420 (11%) adults. The monthly splenectomy rate decreased after 2008 
in adults and, to a lesser extent, in children. For decades, splenectomy was the treatment of choice for 
patients with chronic ITP in case of corticosteroid failure;
45,46 
however, recent data suggest that <25% 
of patients with ITP undergo splenectomy, mostly with a delay from second- to third-line treatment.47 
The reason for this decline are probably various, medical professionals recommend increasingly to 
delay splenectomy but also patients do not accept uncritically the procedure. The optimal role of 
Page 11 of 22
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
12 
 
 
 
splenectomy in chronic ITP treatment in the current era of TPO-RAs still has to be determined. Of 
concern was early splenectomy at the 6-month FU in 4 children and 23 adults. This is not in 
accordance with current guidelines.
9,10
 
 
Limitations 
PARC-ITP is an international registry based on voluntary participation of investigators. Llimitations 
include different data source levels including different countries, institutions, and investigators; 
voluntary basis of data registration; unbalanced number of children and adults; and high percentage of 
patients with loss to FU who were not further treated in a given institution. However among all 
patients with persistent ITP at 6 months, FU information at 12 and/or 24 months was provided for 90% 
of children and adults.In addition, some aspects of the registry questionnaire are defined according to a 
specific time point (e.g., platelet count) and others according to a time interval (e.g., bleeding and 
therapy). To better characterize patients lost to FU, an analysis was conducted to evaluate the effect of 
this bias. Demographic data and clinical characteristics (including initial platelet count, bleeders, and 
initial therapeutic approach) differed, particularly in children lost to FU at 6 months compared with 
those who were not lost. For the group of lost to FU at 12 and 24 months, we found a higher 
percentage of patients in remission at the previous FU in children and adults. In this analysis, we 
included all patients independently, even if FU data were missing at some time points, with the goal to 
describe the registered patients as a whole without artificially selecting a subpopulation of ITP. 
Following this strategy, we used statistical evaluation for selected and clearly defined issues only. 
 
In conclusion, understanding differences and similarities among different age groups with ITP during 
FU may be valuable in characterizing study populations and in better defining inclusion criteria for 
trials and further individualizing diagnosis and management. Future studies will investigate criteria to 
better define age groups. 
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Figure Legends 
 
 
Figure1.  Platelet counts at FU.  
(A) Mean platelet counts in patients with ongoing ITP was similar in children and adults at all FU. 
Children in remission showed a higher platelet count at all FU examinations compared with adults.  
(B) Distribution of platelet count in patients with a chronic ITP at 12 month FU requiring or not 
requiring treatment. 
 
 
Figure 2. Cumulative incidence of remission.  
The cumulative incidence of remission was significantly different between children and adults (log-
rank test, p < 0.001). For this analysis it was assumed that patients achieving remission at 6 or12 
months and consecutively lost to FU were still in remission at 24 months FU. It is of note that patients 
lost to FU at 12 and 24 months had a higher remission rate in the previous FU than patients with FU 
data. 
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Table 1. Initial characteristics of patients with early lost to Follow-up (without 6 month Follow-
up data) compared to patients with FU data 
(% refers to the total number of patients, platelet count x10
9
/l) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*With FU: characterizes patients with Follow-up (FU) information at 12 and/or 24 months. 
 
 
 
 
 
 
 
 
 
 With FU * 
 
Lost to FU at 6 mo p-value 
Total patients  
Children 
Adults 
 
2317 
333 
 
1043 
87 
 
Mean age (SD)/ Median (IQR) 
Children 
Adults 
 
5.5 (4.3)/ 4.2 (2-8.5) 
38.6 (19.3)/ 34.3 (20.3-53) 
 
4.5 (3.7)/ 3.4 (1.6-6.6) 
35.4 (18.1)/ 31.1 (20-49.1) 
 
<0.001 
0.19 
f/m (%) 
Children female 
Adults female 
 
1102(48) 
229 (69) 
 
507 (49) 
43 (49) 
 
0.57 
<0.001 
Mean platelet count, initial (SD)/ 
Median (IQR) 
Children 
Adults 
 
 
17 (18)/ 11 (5-21) 
24 (24)/ 14 (5-36) 
 
 
25 (25)/ 16 (6-36) 
22 (21)/ 14 (5-35) 
 
 
<0.001 
0.81 
No bleedings initial (%) 
Children 
Adults 
 
160 (7) 
99 (30) 
 
289 (28) 
23 (26) 
 
<0.001 
0.55 
Therapy initial yes (%) 
Children 
Adults 
 
1703 (74) 
220 (66) 
 
628 (60) 
60 (69) 
 
<0.001 
0.61 
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 All Remission Ongoing disease 
 Children Adult Children Adult Children Adult 
Total patients (%) 
Female (% of total female) 
Male 
1639 
776 
863 
271 
189 
82 
1160 (71) 
521 (67) 
639 (74) 
133 (49) 
96 (51) 
37 (45) 
479 (29) 
255 (33) 
224 (26) 
138 (51) 
93 (49) 
45 (55) 
Mean age (SD) 
Female 
Male 
5.7 (4.4) 
6.2 (4.5) 
5.3 (4.2) 
39.4 (19.5) 
38.3 (19.2) 
41.8 (20.2) 
5 (4.1) 
5.3 (4.3) 
4.7 (4) 
39.6 (19.5) 
38.2 (19.3) 
43.1 (19.8) 
7.4(4.5) 
7.9 (4.5) 
6.8 (4.4) 
39.2 (19.7) 
38.5 (19.2) 
40.7 (20.6) 
No bleeding (%)† 
Female (% of total female) 
Male 
1215 (74) 
560 (72) 
655 (76) 
205 (76) 
137 (73) 
68 (83) 
1039 (90) 
463 (89) 
576 (90) 
110 (83) 
79 (82) 
31 (84) 
176 (37) 
97 (38) 
79 (35) 
95 (69) 
58 (62) 
37 (82) 
Platelet count (SD) ‡ 
Female 
Male 
191 (126) 
 
183 (125) 
198 (126) 
122 (94) 
 
123 (91) 
120 (100) 
250 (99) 
 
250 (97) 
251 (101) 
197 (80) 
 
193 (78) 
207 (86) 
46 (29) 
 
46 (28) 
46 (30) 
51 (26) 
 
52 (26) 
49 (25) 
Platelet enhancing treatment 
(%)† 
Female (% of total female) 
Male 
 
307 (19) 
 
170 (22) 
137 (16) 
 
109 (40) 
 
82 (43) 
27 (33) 
 
 
86 (7.4) 
 
45 (8.6) 
41 (6.4) 
 
 
37 (28) 
 
28 (29) 
9 (24) 
 
 
221 (46) 
 
125 (49) 
96 (43) 
 
 
72 (52) 
 
54 (58) 
18 (40) 
 
 
 
 (% refers to the total number of patients if not other mentioned, platelet count x109/l) 
 
* Relevant comedication: drugs with known effects on hemostasis (anti-inflammatory drugs, 
anticoagulants, platelet antagonist) 
† in the period of time between 6 and 12 months 
‡ at 12 month 
§ Second line treatment: other drugs than steroids, Anti-D and IVIG 
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